hrcak mascot   Srce   HID

Other
https://doi.org/10.20471/acc.2018.57.03.22

Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report

Robert Šeparović ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Internist Oncology, Zagreb, Croatia
Mirjana Pavlović ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Internist Oncology, Zagreb, Croatia
Tajana Silovski ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Internist Oncology, Zagreb, Croatia
Hrvoje Silovski ; Zagreb University Hospital Centre, Department of Gastrointestinal Surgery, Zagreb, Croatia
Ana Tečić Vuger ; Sestre milosrdnice University Hospital Centre, University Hospital for Tumors, Department of Internist Oncology, Zagreb, Croatia

Fulltext: english, pdf (460 KB) pages 577-579 downloads: 46* cite
APA 6th Edition
Šeparović, R., Pavlović, M., Silovski, T., Silovski, H. & Tečić Vuger, A. (2018). Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report. Acta clinica Croatica, 57 (3.), 577-579. https://doi.org/10.20471/acc.2018.57.03.22
MLA 8th Edition
Šeparović, Robert, et al. "Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report." Acta clinica Croatica, vol. 57, no. 3., 2018, pp. 577-579. https://doi.org/10.20471/acc.2018.57.03.22. Accessed 26 Aug. 2019.
Chicago 17th Edition
Šeparović, Robert, Mirjana Pavlović, Tajana Silovski, Hrvoje Silovski and Ana Tečić Vuger. "Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report." Acta clinica Croatica 57, no. 3. (2018): 577-579. https://doi.org/10.20471/acc.2018.57.03.22
Harvard
Šeparović, R., et al. (2018). 'Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report', Acta clinica Croatica, 57(3.), pp. 577-579. https://doi.org/10.20471/acc.2018.57.03.22
Vancouver
Šeparović R, Pavlović M, Silovski T, Silovski H, Tečić Vuger A. Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report. Acta clinica Croatica [Internet]. 2018 [cited 2019 August 26];57(3.):577-579. https://doi.org/10.20471/acc.2018.57.03.22
IEEE
R. Šeparović, M. Pavlović, T. Silovski, H. Silovski and A. Tečić Vuger, "Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report", Acta clinica Croatica, vol.57, no. 3., pp. 577-579, 2018. [Online]. https://doi.org/10.20471/acc.2018.57.03.22

Abstracts
Sunitinib is an orally administered multikinase inhibitor. This therapy can provoke uncommon side effects such as pancytopenia, tumor lysis syndrome, cardiac disorders, thromboembolic incidents, intestinal perforation, pancreatitis, acute renal failure, etc. We report a case of a 63-year-old female admitted to the hospital due to abdominal pain, nausea, vomiting and elevated blood pressure. One month earlier, sunitinib therapy for metastatic renal cell carcinoma was initiated. During the first cycle of therapy, after three weeks of sunitinib 50 mg daily, symptoms started and she stopped taking the drug. At admission, laboratory tests revealed elevated serum and urine amylase, C-reactive protein, urea and creatinine, and lowered platelet and leukocyte counts and hemoglobin value. Urine test showed proteinuria, erythrocyturia, leukocyturia and granulated cylinder. The patient was diagnosed with acute pancreatitis grade III, acute renal failure grade II, pancytopenia and urinary infection, and was hospitalized for five days. She was treated symptomatically and with antibiotic therapy because of persistently elevated C-reactive protein and pathologic urinary sediment, which led to subjective and clinical improvement. Acute pancreatitis, renal insufficiency and pancytopenia are rarely described side effects of sunitinib therapy, and clear connection between these conditions and drug activity is not yet determined. Medical specialists who prescribe and treat patients with sunitinib should be aware of the possible occurrence of these conditions and perform regular checkups of sunitinib treated patients.

Keywords
Sunitinib; Carcinoma, renal cell; Drug-related side effects and adverse reactions; Pancreatitis; Acute kidney injury; Pancytopenia

Hrčak ID: 216176

URI
https://hrcak.srce.hr/216176

[croatian]

Visits: 84 *